GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Sloan Ratio %

Advanced Oncotherapy (FRA:R3I1) Sloan Ratio % : 3.68% (As of Jun. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Advanced Oncotherapy's Sloan Ratio for the quarter that ended in Jun. 2022 was 3.68%.

As of Jun. 2022, Advanced Oncotherapy has a Sloan Ratio of 3.68%, indicating the company is in the safe zone and there is no funny business with accruals.


Advanced Oncotherapy Sloan Ratio % Historical Data

The historical data trend for Advanced Oncotherapy's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Sloan Ratio % Chart

Advanced Oncotherapy Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.88 -12.46 12.88 1.95 6.63

Advanced Oncotherapy Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.59 1.94 2.77 6.63 3.68

Competitive Comparison of Advanced Oncotherapy's Sloan Ratio %

For the Medical Devices subindustry, Advanced Oncotherapy's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Oncotherapy's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's Sloan Ratio % falls into.



Advanced Oncotherapy Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Advanced Oncotherapy's Sloan Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2021 )-Cash Flow from Operations (A: Dec. 2021 )
-Cash Flow from Investing (A: Dec. 2021 ))/Total Assets (A: Dec. 2021 )
=(-34.709--34.8
--10.939)/166.28
=6.63%

Advanced Oncotherapy's Sloan Ratio for the quarter that ended in Jun. 2022 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2022 )
=(-38.183--31.276
--13.479)/178.45
=3.68%

For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data. Advanced Oncotherapy's Net Income for the trailing twelve months (TTM) ended in Jun. 2022 was -19.688 (Dec. 2021 ) + -18.495 (Jun. 2022 ) = €-38.18 Mil.
Advanced Oncotherapy's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2022 was -22.733 (Dec. 2021 ) + -8.543 (Jun. 2022 ) = €-31.28 Mil.
Advanced Oncotherapy's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2022 was -7.479 (Dec. 2021 ) + -6 (Jun. 2022 ) = €-13.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advanced Oncotherapy  (FRA:R3I1) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2022, Advanced Oncotherapy has a Sloan Ratio of 3.68%, indicating the company is in the safe zone and there is no funny business with accruals.


Advanced Oncotherapy Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Advanced Oncotherapy Business Description

Traded in Other Exchanges
N/A
Address
4 Tenterden Street, Third Floor, London, GBR, W1S 1TE
Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy Headlines

No Headlines